Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
J Mol Diagn. 2013 Mar;15(2):171-6. doi: 10.1016/j.jmoldx.2012.09.003. Epub 2012 Dec 27.
There is growing demand for routine identification of actionable mutations in clinical cancer specimens. Genotyping platforms must provide rapid turnaround times and work effectively with limited amounts of formalin-fixed, paraffin-embedded (FFPE) tissue specimens that often yield poor quality DNA. We describe semiconductor-based sequencing of DNA from FFPE specimens using a single-tube, multiplexed panel of 190 amplicons targeting 46 cancer genes. With just 10 ng of input DNA, average read depths of 2000× can be obtained in 48 hours, with >95% of the reads on target. A validation set of 45 FFPE tumor specimens containing 53 point mutations previously identified with a mass spectrometry-based genotyping platform, along with 19 indels ranging from 4 to 63 bp, was used to evaluate assay performance. With a mutant allele ratio cutoff of 8%, we were able to achieve 100% sensitivity (95% CI = 97.3% to 100.0%) and 95.1% specificity (95% CI = 91.8% to 98.0%) of point mutation detection. All indels were visible by manual inspection of aligned reads; 6/9 indels ≤12 bp long were detected by the variant caller software either exactly or as mismatched nucleotides within the indel region. The rapid turnaround time and low input DNA requirements make the multiplex PCR and semiconductor-based sequencing approach a viable option for mutation detection in a clinical laboratory.
临床癌症标本中常见特定基因突变的鉴定需求日益增长。基因分型平台必须提供快速的周转时间,并能有效地处理数量有限的福尔马林固定、石蜡包埋(FFPE)组织标本,这些标本通常产生质量较差的 DNA。我们描述了使用单管、190 个针对 46 个癌症基因的扩增子的多重检测 panel 对 FFPE 标本进行基于半导体的测序。只需 10ng 的输入 DNA,即可在 48 小时内获得平均深度为 2000×的读数,>95%的读数在靶标上。使用经过验证的 45 个包含 53 个先前使用基于质谱的基因分型平台鉴定的点突变的 FFPE 肿瘤标本和 19 个长度为 4 至 63bp 的插入缺失,评估了检测方法的性能。采用突变等位基因比例截断值为 8%,我们能够实现 100%的敏感性(95%置信区间=97.3%至 100.0%)和 95.1%的特异性(95%置信区间=91.8%至 98.0%)的点突变检测。通过对齐读取的手动检查可以看到所有的插入缺失;6/9 个长度≤12bp 的插入缺失通过变异调用软件被准确检测到,或者在插入缺失区域被检测为错配核苷酸。快速的周转时间和低输入 DNA 要求使多重 PCR 和基于半导体的测序方法成为临床实验室中突变检测的可行选择。